Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.41 |
| ▸ | FLT3 | P36888 | 3/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.38 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.38 |
| ▸ | RIOK2 | Q9BVS4 | 2/20 | 0.38 |
| ▸ | TLK1 | Q9UKI8 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5642412 | 0.91 | MEN1 (0.42) | LRRK2FLT3KDRFLT1PDGFRB | |
| SCHEMBL6722350 | 0.91 | KDR (0.51) | LRRK2FLT3KDRFLT1PDGFRB | |
| SCHEMBL5640837 | 0.89 | PDGFRB (0.43) | FLT3KDRFLT1ZAP70PDGFRB | |
| SCHEMBL5641003 | 0.81 | LRRK2 (0.41) | LRRK2FLT3PSEN1PSEN2APH1B | |
| SCHEMBL6727036 | 0.80 | KDR (0.53) | LRRK2FLT3KDRFLT1PDGFRB | |
| SCHEMBL2113945 | 0.79 | LRRK2 (0.45) | LRRK2FLT3PSEN1PSEN2APH1B | |
| SCHEMBL5628262 | 0.75 | KDR (0.51) | LRRK2FLT3PSEN1PSEN2APH1B | |
| SCHEMBL5628630 | 0.75 | KDR (0.51) | LRRK2FLT3PSEN1PSEN2APH1B | |
| SCHEMBL5639627 | 0.74 | MEN1 (0.42) | KDRTGM2PDGFRBEGFRRET | |
| SCHEMBL2117957 | 0.72 | MEN1 (0.46) | KDRPDGFRBEGFRRETPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | claimed |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | MKI67, CCNA1, CCNI | LRRK2 1606/4885FLT3 2255/4885PSEN1 2543/4885 |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | FLT3, FLI1, MCL1 | LRRK2 2621/4885FLT3 1/4885PSEN1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.